Page 1

Fate THERAPEUTICS Exhibit 99.1 Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819 , the First - ever iPSC - derived CAR T - cell Therapy ; Off - the - Shelf Product Candidate Derived from Clonal Master iPSC Line with Novel CD19 - specific IXX CAR Integrated into TRAC Locus FT516 Interim Phase 1 Data for Relapsed / Refractory Lymphoma Featured at ASCO ; 8 of 11 Patients in Dose Cohorts 2 and 3 Achieved Objective Response , including 6 Patients with Complete Response Interim Phase 1 Data from FT516 and FT538 Programs for Relapsed / Refractory AML Highlighted at May Investor Event ; 5 of 12 Patients Achieved Objective Response with Complete Clearance of Bone Marrow Leukemic Blasts New Phase 1 Clinical Data from FT516 and FT596 Programs in Relapsed / Refractory Lymphoma to be Featured at Investor Event on August 19 San Diego , CA - August 4 , 2021 – Fate Therapeutics , Inc. ( NASDAQ : FATE ) , a clinical - stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer , today reported business highlights and financial results for the second quarter ended June 30 , 2021 . " We are very pleased with the early clinical safety and activity we have observed with our off - the - shelf , iPSC - derived NK cell programs in relapsed / refractory lymphoma and acute myeloid leukemia , where interim Phase 1 data indicate FT516 and FT538 are well tolerated and can deliver complete responses for patients . We look forward to sharing additional clinical data from our FT516 and FT596 programs in B - cell lymphoma at our upcoming investor event , " said Scott Wolchko , President and Chief Executive Officer of Fate Therapeutics . “ Additionally , treatment of the first patient with FT819 , the first - ever iPSC - derived T - cell therapy to undergo clinical investigation , is a landmark achievement and further demonstrates the Company's leadership in off the - shelf , iPSC - derived cell therapy and the versatility of its proprietary iPSC Product Platform . ” B - cell Malignancy Disease Franchise Positive Interim Phase 1 Clinical Data of FT516 Presented at ASCO . At the 2021 American Society of Clinical Oncology Annual Meeting ( ASCO ) held in June , the Company highlighted interim clinical data from its dose - escalating Phase 1 study of FT516 in combination with rituximab for the treatment of relapsed / refractory B - cell lymphoma ( BCL ) . As of the data cutoff date of March 11 , 2021 , eight of eleven patients ( 73 % ) in Dose Cohorts 2 and 3 ( n = 4 at 90 million cells / dose and n = 7 at 300 million cells / dose , respectively ) achieved an objective response , including six patients ( 55 % ) who achieved a complete response . Notably , two of four patients previously treated with autologous CD19 CAR - T cell therapy achieved a complete response . The FT516 treatment regimen was well tolerated , and no treatment - emergent adverse events of any grade of cytokine release syndrome ( CRS ) , immune effector cell